RecruitingPhase 2NCT06702826

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

Efficacy and Safety of Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases From Non-small Cell Lung Cancer (NSCLC) : a Single-arm, Open-label, Phase II Clinical Trial

Sponsor

Rongrong Zhou

Enrollment

20 participants

Start Date

Nov 1, 2024

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer Brain Metastases Immunotherapy Stereotactic Radiation

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC). The main questions it aims to answer are: * Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results? * Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC： * Receive Cadonilimab combined with SRT for brain lesions. * Visit the hospital regularly once every 12 weeks for checkups and tests

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether combining a targeted brain radiation treatment (stereotactic radiosurgery) with an immunotherapy drug called cadonilimab can control brain metastases in people with non-small cell lung cancer (NSCLC) whose cancer has spread to the brain after previous treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed non-small cell lung cancer - Your cancer spread to the brain after first-line treatment, and you previously responded to a checkpoint inhibitor drug - Your brain metastases are small enough to be treated with focused radiation (SRS/FSRT) - You are in good physical condition (ECOG 0–1) **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your brain metastases are too large for the focused radiation technique - Your organ function (liver, kidneys, heart) is not adequate - Your expected survival is less than 12 weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCadonilimab combined with SRS

Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone

Locations(1)

Xiangya Hospital, Central South University

Changsha, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06702826

Related Trials

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

NCT074137571 location

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533283 locations

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT0500540346 locations

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT070284898 locations